1266.8000 1.50 (0.12%)
NSE Sep 01, 2025 09:29 AM
Volume: 4,475
 

1266.80
0.12%
ICICI Securities Limited
Thyrocare Technologies’ (Thyrocare) core business grew 18% YoY in Q4FY24 driven by 13% YoY jump in sales from franchisee and 40% from partnerships (excluding API & B2G). EBITDA margin at 21.9% was weaker (I-Sec: 25.1%) as the company has
inched up investments in marketing and promotion for new bundled test programmes like Jaanch, Her Check and Troponin I and for other initiatives.
Number of FII/FPI investors increased from 80 to 99 in Jun 2025 qtr.
More from Thyrocare Technologies Ltd.
Recommended